Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 0.81 |
| ▸ | DRD2 | P14416 | 10/20 | 0.81 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22892399 | 1.00 | DRD3 (0.81) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL21040963 | 0.89 | DRD3 (1.00) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL22892397 | 0.87 | DRD3 (0.78) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL21041441 | 0.87 | DRD3 (0.78) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL21041406 | 0.86 | DRD3 (0.74) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL21040985 | 0.85 | DRD3 (0.75) | DRD3DRD2HTR2A | |
| SCHEMBL22990972 | 0.77 | DRD3 (1.00) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL22990979 | 0.77 | DRD3 (1.00) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL21041466 | 0.76 | DRD3 (0.64) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL22990956 | 0.76 | DRD3 (1.00) | DRD3DRD2HTR2AHTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345716-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2022-05-31 | — | — | US | disclosed |
| US-20210009607-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2021-01-14 | — | — | US | disclosed |
| US-10870660-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2020-12-22 | — | — | US | disclosed |
| US-20190161501-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345716-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | DRD3, DRD4, DRD2 | DRD3 1/4885DRD2 3/4885HTR2A 227/4885 |
| US-10870660-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | DRD3, DRD4, DRD2 | DRD3 1/4885DRD2 3/4885HTR2A 227/4885 |
| US-20210009607-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | DRD3, DRD4, DRD2 | DRD3 1/4885DRD2 3/4885HTR2A 227/4885 |
| US-20190161501-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | DRD3, DRD4, DRD2 | DRD3 1/4885DRD2 3/4885HTR2A 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.